Promoter holding
64.27%
JC
Jubilant Chemsys Limited - Due diligence report
A 360° intelligence report on Jubilant Chemsys: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Jubilant Chemsys — 360° Intelligence Report
Generated from MCA filings & public records66/100
Trust Score
Moderate
Jubilant Chemsys is assessed as Moderate with a Trust Score of 66/100. Jubilant Chemsys is a public limited indian non-government company incorporated in 2004, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 23 Jul 2026 from the latest processed filings. Jubilant Chemsys Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
66/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
23/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 0 open (-) · 1 satisfied (5.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Ing Vysya Bank Limited | 1 | 48.0 cr |
Compliance Score: 23/100 Caution Indicated
- Company status is "Amalgamated" - not Active.
- Last balance sheet is for Mar 2019 - filings overdue.
- Litigation present in 1 court forum(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAJESH KUMAR SRIVASTAVA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARUN KUMAR SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MARCELLUS JOHANNES VELTEROP | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANANT PANDE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIKAS SHREEKRISHNA SHIRSATH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NOOPUR AGARWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2018 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Jubilant Clinsys Limited | Subsidiary Company | 74.00% |
Key managerial personnel: VIKAS SHREEKRISHNA SHIRSATH (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 55
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
Operating for 21+ years.
Active EPFO - real payroll on record.
Distress signals & risk flags
Statutory filings appear overdue.
Adverse company status: Amalgamated.
Compliance score is weak (23/100).
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence46/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment73/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events28 Nov 2019
Director appointed
ANANT PANDE (Additional Director)
23 Sep 2019
Last AGM held
Annual general meeting
31 Mar 2019
Latest balance sheet
Filed with ROC
27 Feb 2019
Securities allotted
6200000 Equity Shares Without Differential Rights - 6.20 cr raised
31 Oct 2018
Director ceased
ARUN KUMAR SHARMA
Director ceased
MARCELLUS JOHANNES VELTEROP
29 Oct 2018
Director ceased
ASHUTOSH AGARWAL
03 Oct 2018
Director appointed
ARUN KUMAR SHARMA (Director)
Director appointed
MARCELLUS JOHANNES VELTEROP (Director)
20 Sep 2018
Director ceased
RAJESH KUMAR SRIVASTAVA
Director ceased
BENNY THOMAS
05 Sep 2018
Director appointed
RAJESH KUMAR SRIVASTAVA (Director)
Director appointed
VIKAS SHREEKRISHNA SHIRSATH (Managing Director)
28 Mar 2018
Director ceased
SHYAM NATH SINGH
Director ceased
STEVEN MICHAEL HUTCHINS
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Net worth is positive.
6 active director(s) / partner(s); board looks stable and experienced.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2018 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Enviro Policy Research India Private Limited | U74999MH2015PTC266078 | Thane, Maharashtra, India |
| Indian Institute Of Psychometry | U72200WB1978NPL031582 | Kolkata, West Bengal, India |
| Neutrinos Solutions Private Limited | U72200KA2015PTC080278 | Bangalore, Karnataka, India |
| Avieum Life Sciences | U73100PN2017PTC167898 | Pune, Maharashtra, India |
| Falco Emotors Private Limited | U31100PN2012PTC144771 | Pune, Maharashtra, India |
| Gangagen | U72100KA2000PTC027824 | Bangalore, Karnataka, India |
| Pharmazell (Vizag) Private Limited | U02423TN2007PTC127518 | Chennai, Tamil Nadu, India |
| Biocon Research Limited | U73100KA2008PLC046583 | Bangalore, Karnataka, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Jubilant Chemsys before audits and certifications: compliance score 23/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Jubilant Chemsys: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Jubilant Chemsys - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 66/100, distress signals and MSME payment-delay disclosures - know whether Jubilant Chemsys pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Jubilant Chemsys - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Jubilant Chemsys an active company?
Jubilant Chemsys has MCA status “Amalgamated” with a compliance score of 23/100 (Caution Indicated).
Is Jubilant Chemsys financially healthy?
Jubilant Chemsys has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Jubilant Chemsys?
Its overall Trust Score is 66/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Jubilant Chemsys?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.
Does Jubilant Chemsys have loans or charges against its assets?
No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Jubilant Chemsys up to date with its ROC filings?
Last balance sheet is for Mar 2019 - filings overdue. Overall compliance score: 23/100 (Caution Indicated).
Is it risky to lend to Jubilant Chemsys?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
